Clinical Trials

UMC participates in several National Cancer Group Programs and Protocols investigating new treatments. UMC also participates in several multicenter trials of new chemotherapeutic agents. Current trials include:

S9811 - Phase II
Southwest Oncology Group
Phase II Study of Hydroxyurea for Unresectable Meningioma

Treatment: Hydroxyurea

Eligibility Criteria: Histologically documented primary, recurrent or residual benign meningioma which is unresectable, biopsy slides must be available for pathology review; patient must have measurable disease by CT or MRI scan; patient must have either progressive meningioma or progressive neurologic deficit; patients with malignant meningioma or meningiomatosis are not eligible; patient should have already received radiotherapy unless radiotherapy has been refused. If prior RT, treatment must have been completed at least one year prior to study entry, with documented progressive disease since completion of RT. Pt. must be >= 18 years, SWOG PS 0-2, no prior cytotoxic chemo. for meningioma; prior RU-486 is allowed; prior glucocorticoids and hormone replacement therapy are allowed.

S0001 - Phase III
Southwest Oncology Group
A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma

Treatment: O6-Benzylguanine, BCNU, Radiation Therapy

Eligibility Criteria: Pts. must have hist. conf. dx of GBM/ gliosarcoma; bx or srg resection w/in 28 days prior to registration;MRI w/gadolinium after surgery, but before registration if tumor removal is greater than simple bx; pts who have had a simple bx only require the preoperative MRI w/gadolinium; note: bx will be considered a procedure done for diagnostic rather than therapeutic purposes with NO attempt at debulking; no prior radiation therapy delivered cephalad to the interspace between the 7th cervical vertebral body and the 1st thoracic vertebral body; cannot have 3 or more noncontiguous sites of tumor based on T2 MRI; no prior chemo.; no prior concomitant drugs with antineoplastic activity; no other invest. drugs or hormanal therapy; use of corticosteroids allowed provided that the dose is stable or decreasing following initial srg. prior to obtaining MRI; institutions must be willing to submit 1-2 H&E slides for central path review and 3-9 unstained slides for AGT IHC assay; serum creatinine less than or equal to 1.5 x IULN or creatinine clearance greater than or equal to 60 ml/min, PT/PTT less than or equal to 120% of the ULN w/i 28 days prior to registration; DLCO greater than 70% of predicted within 42 days prior to registration; pts must be at least 18 yrs of age; PS of less than or equal to 2; pts must not be known to be HIV positive; pts must not be pregnant or nursing;pts must not have known allergies to any of the study drugs; pts must not have other medical illesses which in the Inv's opinion cannot be adequately controlled (see Sect 5.15). Note: Pts may have a CT scan w/IV contrast if MRI is not medically feasible